Literature DB >> 17186015

Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects.

T Wenger1, J Mattern, T L Haas, M R Sprick, H Walczak, K-M Debatin, M W Büchler, I Herr.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, which selectively induces apoptosis in many transformed cells without apparent toxic side effects in normal tissue. We recently described the construction and characterization of a lentiviral vector for expression of TRAIL. In this report, we evaluate its suitability for therapeutic application. In vitro, we observed specific induction of apoptosis upon transduction in human lung cancer cells. Cell death was partially dependent on successful integration and TRAIL expression by the vectors, but was to some extent mediated by protein carryover, as we found TRAIL protein associated with virus particles. Transduction of subcutaneously growing lung tumors on nude mice with lentiviral TRAIL mediated a transient suppression of tumor growth. Analysis of tumor sections revealed that transduction efficiency of lentiviral control vector but not of lentiviral TRAIL vector was high. This was because of the direct cytotoxic activity of recombinant TRAIL present in viral particles, which prevented efficient tumor transduction. These data therefore suggest that enveloped viral vectors constitutively expressing TRAIL are well suited for ex vivo applications, such as the transduction of tumor-homing cells, but may have a lower effect when used directly for the transduction of tumor cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17186015     DOI: 10.1038/sj.cgt.7701016

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  8 in total

1.  Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.

Authors:  Wei Zhu; Hongwei Zhang; Yi Shi; Mangen Song; Bijun Zhu; Lai Wei
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

Review 2.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 3.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

Review 4.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

5.  Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice.

Authors:  Liu Zheng; Zhang Weilun; Jiang Minghong; Zhang Yaxi; Liu Shilian; Liu Yanxin; Zheng Dexian
Journal:  BMC Cancer       Date:  2012-04-24       Impact factor: 4.430

6.  An Lnc RNA (GAS5)/SnoRNA-derived piRNA induces activation of TRAIL gene by site-specifically recruiting MLL/COMPASS-like complexes.

Authors:  Xin He; Xinxin Chen; Xue Zhang; Xiaobing Duan; Ting Pan; Qifei Hu; Yijun Zhang; Fudi Zhong; Jun Liu; Hong Zhang; Juan Luo; Kang Wu; Gao Peng; Haihua Luo; Lehong Zhang; Xiaoxi Li; Hui Zhang
Journal:  Nucleic Acids Res       Date:  2015-03-16       Impact factor: 16.971

7.  Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.

Authors:  Lyse A Norian; Britnie R James; Thomas S Griffith
Journal:  Cancers (Basel)       Date:  2011-02-10       Impact factor: 6.639

8.  Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.

Authors:  Andrea Mohr; Mark Lyons; Laura Deedigan; Tina Harte; Georgina Shaw; Linda Howard; Frank Barry; Tim O'Brien; Ralf Zwacka
Journal:  J Cell Mol Med       Date:  2008-03-28       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.